HEADLINE: Inhaled drug for lung infections

[Guest guest]

Chemist & Druggist

                                 March 22, 2003

HEADLINE: Inhaled drug for lung infections

    An inhaled antibiotic for treating lung infections in cystic fibrosis

patients has been launched by Profile Pharma.

   Promixin Powder for Nebuliser Solution, which contains one million IU

(approximately 80mg) of colistimethate per vial, is indicated for the

treatment

of Pseudomonas aeruginosa lung infections.

   Dosage is determined by infection type and severity, bacteria

sensitivity,

and the patient's age, weight and renal function.

    Although Promixin may be used with any conventional nebuliser

suitable for

delivery of antibiotic solutions, the company will supply patients with

its own

delivery device, Prodose AAD Syfree of charge.

-----------------------

Canada NewsWire

                           March 26, 2003, Wednesday

HEADLINE: Cystic Fibrosis Phase II Clinical Trial Update;

(TSXV: BCY)

DATELINE: TORONTO, March 26

   BCY LifeSciences Inc. announced today that the

Phase II clinical trial of its lead compound, DCF 987, for treatment of

Cystic

Fibrosis (CF) is progressing on schedule. DCF 987 is administered by

inhalation to CF patients age sixteen years or older. The company plans

to

include CF patients younger than sixteen in a subsequent clinical trial.

    In an earlier release the company noted that the first patient was

entered into the trial on January 7, 2003. Enrollment in the trial has

continued at all sites, with over one-half of the patients planned for

the

trial, now enrolled. Eleven of these patients have completed therapy and

the

subsequent follow-up visit. As is normal, in clinical trials, there have

been

patients who have started in the trial, who have withdrawn. The company

notes

that this number is lower than the number that had been allowed for in

the

trial design. The company notes, that as the trial is double blinded, the

company will not know until the conclusion of the trial, which patients

were

on active medication or placebo.

    " We are pleased with the enrollment to date and that all centers are

actively involved in recruiting additional patients " stated Lorne Meikle,

President & CEO of the Company. The company notes, that if enrollment

continues at the present rate, the trial should be finished mid year

2003.

       About BCY LifeSciences

    BCY LifeSciences is a pharmaceutical development company dedicated to

acquiring and developing innovative pharmaceutical products or

technologies

that serve unmet medical needs. The Company's initial technologies are

targeting respiratory diseases, with an initial focus on cystic fibrosis

(CF).

This press release, as well as other press releases and corporate

information,

can be found on the Company web site: www.BCYLifesciences.com.

       This news release contains projections and other forward-looking

    statements regarding future events. Such statements are predictions,

    which may involve known and unknown risks, uncertainties and other

    factors, which could cause the actual events or results and company

plans

    and objectives to differ materially from those expressed. For

information

    concerning factors affecting the company's business, the reader is

    referred to the documents that the company files from time to time

with

    applicable Canadian securities and regulatory authorities.

       The TSX Venture Exchange has not reviewed and does not accept

    responsibility for the adequacy or accuracy of this statement.

   VIEW ADDITIONAL COMPANY-SPECIFIC INFORMATION:

http://www.newswire.ca/cgi-bin/inquiry.cgi?OKEY=19050

CONTACT: contact: Lorne Meikle, President and CEO, BCY LifeSciences Inc.,

(416)

Becki

YOUR FAVORITE LilGooberGirl

YOUNGLUNG EMAIL SUPPORT LIST

www.topica.com/lists/younglung

Pediatric Interstitial Lung Disease Society

http://groups.yahoo.com/group/InterstitialLung_Kids/

[Guest guest]

I don't understand... why does this say that the product is launched

and then below it says it's only in phase II's... which means that

it is years from launch and has only proven basic safety and not

clinical efficacy.

> Chemist & Druggist

>

>                                  March 22, 2003

>

> HEADLINE: Inhaled drug for lung infections

>

>     An inhaled antibiotic for treating lung infections in cystic

fibrosis

> patients has been launched by Profile Pharma.

>

>    Promixin Powder for Nebuliser Solution, which contains one

million IU

> (approximately 80mg) of colistimethate per vial, is indicated for

the

> treatment

> of Pseudomonas aeruginosa lung infections.

>

>    Dosage is determined by infection type and severity, bacteria

> sensitivity,

> and the patient's age, weight and renal function.

>     Although Promixin may be used with any conventional nebuliser

> suitable for

> delivery of antibiotic solutions, the company will supply patients

with

> its own

> delivery device, Prodose AAD Syfree of charge.

> -----------------------

> Canada NewsWire

>                            March 26, 2003, Wednesday

>

> HEADLINE: Cystic Fibrosis Phase II Clinical Trial Update;

> (TSXV: BCY)

>

> DATELINE: TORONTO, March 26

>

>    BCY LifeSciences Inc. announced today that the

> Phase II clinical trial of its lead compound, DCF 987, for

treatment of

> Cystic

> Fibrosis (CF) is progressing on schedule. DCF 987 is administered

by

> inhalation to CF patients age sixteen years or older. The company

plans

> to

> include CF patients younger than sixteen in a subsequent clinical

trial.

>     In an earlier release the company noted that the first patient

was

> entered into the trial on January 7, 2003. Enrollment in the trial

has

> continued at all sites, with over one-half of the patients planned

for

> the

> trial, now enrolled. Eleven of these patients have completed

therapy and

> the

> subsequent follow-up visit. As is normal, in clinical trials,

there have

> been

> patients who have started in the trial, who have withdrawn. The

company

> notes

> that this number is lower than the number that had been allowed

for in

> the

> trial design. The company notes, that as the trial is double

blinded, the

> company will not know until the conclusion of the trial, which

patients

> were

> on active medication or placebo.

>     " We are pleased with the enrollment to date and that all

centers are

> actively involved in recruiting additional patients " stated Lorne

Meikle,

> President & CEO of the Company. The company notes, that if

enrollment

> continues at the present rate, the trial should be finished mid

year

> 2003.

>

>        About BCY LifeSciences

>     BCY LifeSciences is a pharmaceutical development company

dedicated to

> acquiring and developing innovative pharmaceutical products or

> technologies

> that serve unmet medical needs. The Company's initial technologies

are

> targeting respiratory diseases, with an initial focus on cystic

fibrosis

> (CF).

> This press release, as well as other press releases and corporate

> information,

> can be found on the Company web site: www.BCYLifesciences.com.

>

>        This news release contains projections and other forward-

looking

>     statements regarding future events. Such statements are

predictions,

>     which may involve known and unknown risks, uncertainties and

other

>     factors, which could cause the actual events or results and

company

> plans

>     and objectives to differ materially from those expressed. For

> information

>     concerning factors affecting the company's business, the

reader is

>     referred to the documents that the company files from time to

time

> with

>     applicable Canadian securities and regulatory authorities.

>

>        The TSX Venture Exchange has not reviewed and does not

accept

>     responsibility for the adequacy or accuracy of this statement.

>

>    VIEW ADDITIONAL COMPANY-SPECIFIC INFORMATION:

> http://www.newswire.ca/cgi-bin/inquiry.cgi?OKEY=19050

>

> CONTACT: contact: Lorne Meikle, President and CEO, BCY

LifeSciences Inc.,

> (416)

>

>

>

> Becki

> YOUR FAVORITE LilGooberGirl

> YOUNGLUNG EMAIL SUPPORT LIST

> www.topica.com/lists/younglung

> Pediatric Interstitial Lung Disease Society

> http://groups.yahoo.com/group/InterstitialLung_Kids/

>

>

>

[Guest guest]

I read it and to me it looked like it was two separate articles and

two different medications.

-- In cfparents , " birchnymph " <serein@w...> wrote:

> I don't understand... why does this say that the product is

launched

> and then below it says it's only in phase II's... which means that

> it is years from launch and has only proven basic safety and not

> clinical efficacy.